These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Ling H; Burns TL; Hilleman DE Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905 [TBL] [Abstract][Full Text] [Related]
26. Discovery Approaches for Novel Dyslipidemia Drugs. Maqbool F; Safavi M; Bahadar H; Rahimifard M; Niaz K; Abdollahi M Curr Drug Discov Technol; 2015; 12(2):90-116. PubMed ID: 26135857 [TBL] [Abstract][Full Text] [Related]
27. Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Johnston TP; Korolenko TA; Pirro M; Sahebkar A Pharmacol Res; 2017 Jun; 120():219-225. PubMed ID: 28408313 [TBL] [Abstract][Full Text] [Related]
28. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Shen L; Peng H; Xu D; Zhao S Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522 [TBL] [Abstract][Full Text] [Related]
29. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
30. Homozygous familial hypercholesterolaemia: update on management. France M Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828 [TBL] [Abstract][Full Text] [Related]
31. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Wójcik C Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791 [TBL] [Abstract][Full Text] [Related]
32. Proprotein Convertase Subtilism/Kexin 9 (PCSK9) Inhibitors: Adding to the Armamentarium of the Primary Care Physician. Coy K; Stys A; Stys T; DeVries J S D Med; 2021 Oct; 74(10):454-456. PubMed ID: 34995425 [TBL] [Abstract][Full Text] [Related]
33. Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? Gadi R; Figueredo VM J Cardiovasc Med (Hagerstown); 2015 Jan; 16(1):1-10. PubMed ID: 25379719 [TBL] [Abstract][Full Text] [Related]
34. Investigational therapies for the treatment of atherosclerosis. Tomkin GH; Owens D Expert Opin Investig Drugs; 2014 Oct; 23(10):1411-21. PubMed ID: 24857672 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. Okere AN; Serra C Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279 [TBL] [Abstract][Full Text] [Related]